152 related articles for article (PubMed ID: 25340261)
1. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria.
Ali Z; Mishra N; Baldi A
Artif Cells Nanomed Biotechnol; 2016; 44(2):545-9. PubMed ID: 25340261
[TBL] [Abstract][Full Text] [Related]
2. Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance.
Nnamani PO; Ugwu AA; Ibezim EC; Kenechukwu FC; Akpa PA; Ogbonna JN; Obitte NC; Odo AN; Windbergs M; Lehr CM; Attama AA
Int J Nanomedicine; 2016; 11():6365-6378. PubMed ID: 27932882
[TBL] [Abstract][Full Text] [Related]
3. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.
Nnamani PO; Hansen S; Windbergs M; Lehr CM
Int J Pharm; 2014 Dec; 477(1-2):208-17. PubMed ID: 25290810
[TBL] [Abstract][Full Text] [Related]
4. An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether.
Memvanga PB; Coco R; Préat V
J Control Release; 2013 Dec; 172(3):904-13. PubMed ID: 24021359
[TBL] [Abstract][Full Text] [Related]
5. In vivo Antiplasmodial Activity of Curcumin-Loaded Nanostructured Lipid Carriers.
Rashidzadeh H; Salimi M; Sadighian S; Rostamizadeh K; Ramazani A
Curr Drug Deliv; 2019; 16(10):923-930. PubMed ID: 31663477
[TBL] [Abstract][Full Text] [Related]
6. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
7. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity.
Parashar D; Aditya NP; Murthy RS
Drug Deliv; 2016; 23(1):123-9. PubMed ID: 24786480
[TBL] [Abstract][Full Text] [Related]
8. Arthemeter-loaded lipid nanoparticles produced by modified thin-film hydration: Pharmacokinetics, toxicological and in vivo anti-malarial activity.
Aditya NP; Patankar S; Madhusudhan B; Murthy RS; Souto EB
Eur J Pharm Sci; 2010 Aug; 40(5):448-55. PubMed ID: 20493255
[TBL] [Abstract][Full Text] [Related]
9. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
10. Parasite impairment by targeting Plasmodium-infected RBCs using glyceryl-dilaurate nanostructured lipid carriers.
Jain SA; Basu H; Prabhu PS; Soni U; Joshi MD; Mathur D; Patravale VB; Pathak S; Sharma S
Biomaterials; 2014 Aug; 35(24):6636-45. PubMed ID: 24818881
[TBL] [Abstract][Full Text] [Related]
11. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
12. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.
Yu Q; Hu X; Ma Y; Xie Y; Lu Y; Qi J; Xiang L; Li F; Wu W
Drug Deliv; 2016 May; 23(4):1469-75. PubMed ID: 27187522
[TBL] [Abstract][Full Text] [Related]
13. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles.
Omwoyo WN; Melariri P; Gathirwa JW; Oloo F; Mahanga GM; Kalombo L; Ogutu B; Swai H
Nanomedicine; 2016 Apr; 12(3):801-809. PubMed ID: 26724538
[TBL] [Abstract][Full Text] [Related]
14. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
15. Teratogenicity of Artemether-Clindamycin Nanostructured Lipid Carriers in Rats.
Jain SA; Awale M; Pathak S; Vanage G; Patravale VB; Sharma S
Int J Toxicol; 2016 Jul; 35(4):420-8. PubMed ID: 27278417
[TBL] [Abstract][Full Text] [Related]
16. Development of SMEDDS using natural lipophile: application to beta-Artemether delivery.
Mandawgade SD; Sharma S; Pathak S; Patravale VB
Int J Pharm; 2008 Oct; 362(1-2):179-83. PubMed ID: 18652886
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers.
Xu X; Zhao C; Yang H; Jian Y; Zhang Z; Huang Y
Drug Deliv; 2011; 18(7):485-92. PubMed ID: 21692681
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles.
Omwoyo WN; Ogutu B; Oloo F; Swai H; Kalombo L; Melariri P; Mahanga GM; Gathirwa JW
Int J Nanomedicine; 2014; 9():3865-74. PubMed ID: 25143734
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of silybin-loaded nanostructured lipid carriers.
Jia LJ; Zhang DR; Li ZY; Feng FF; Wang YC; Dai WT; Duan CX; Zhang Q
Drug Deliv; 2010 Jan; 17(1):11-8. PubMed ID: 19941406
[TBL] [Abstract][Full Text] [Related]
20. Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids.
Chinaeke EE; Chime SA; Onyishi VI; Attama AA; Okore VC
Drug Deliv; 2015; 22(5):652-65. PubMed ID: 24479677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
